奥扎格雷联合吡拉西坦对急性脑梗死患者神经功能缺损的疗效分析  

The Clinical Analysis of Ozagrel Combined with Piracetam in the Treatment of Acute Cerebral Infarction with Neurological Defect

作　　者：黄宇青[1] 夏峰[2] 韩霞[1] 闫小峰[1] 高佩佩[1] HUANG Yu-qing XIA Feng HAN Xia YAN Xiao-feng GAO Pei-pei(Neurology, Xianyang Hospital of Yan ＇an University, Xianyang, Shaanxi, 712000, China Neurology, Xijing Hospital, Xi＇an, Shaanxi, 710032, China)

机构地区：[1]延安大学咸阳医院神经内科,陕西咸阳712000 [2]西京医院神经内科,陕西西安710032

出　　处：《现代生物医学进展》2016年第36期7194-7196,7167,共4页Progress in Modern Biomedicine

摘　　要：目的:探讨奥扎格雷联合吡拉西坦对急性脑梗死患者神经功能缺损的疗效。方法:选取200例急性脑梗死患者,按照入院时间顺序不同分为两组,奥扎格雷组(92例)静脉滴注奥扎格雷钠注射液治疗,联合用药组(108例)静脉滴注奥扎格雷钠注射液联合吡拉西坦注射液治疗。观察并记录两组治疗前治疗后神经功能缺损,疗效,日常生活能力及随访1个月期间不良反应发生情况,评价奥扎格雷联合吡拉西坦对急性脑梗死患者神经功能缺损的疗效。结果:与治疗前相比,治疗后两组ESS评分均明显增加(P<0.05),且联合用药组在治疗后各时间段均明显高于奥扎格雷组(P<0.05)。治疗后14 d,联合用药组有效率为76.8%,奥扎格雷组为60.9%,联合用药组有效率明显高于奥扎格雷组;治疗后两组Barthel评分明显高于治疗前(P<0.05),且联合用药组高于奥扎格雷组(P<0.05)。随访1个月期间,两组不良反应率比较,差异没有统计学意义(P>0.05)。结论:奥扎格雷联合吡拉西坦能明显改善急性脑梗死患者神经功能缺损情况,提高患者生活能力,用药安全,值得临床推广使用。Objective： Discuss the clinical analysis of ozagrel combined with piracetam in the treatment of acute cerebral infarc- tion with neurological defect. Methods： 200 patients diagnosed acute cerebral infarction were selected and divided into two groups ac- cording to the sequence of admission time. The ozagrel group （92 cases） was given ozagrel injection, and the drug combination group （108 cases） was adopted ozagrel injection and piracetam. The efficacy of ozagrel and piracetam in the treatment of acute cerebral infarc- tion with neurological defect was evaluated by neurologic impairment, efficacy, activities of daily living and adverse reaction during 1 month follow-up. Results： Compared with the score before surgery, the ESS scores were increased apparently in two groups after therapy （P〈0.05）. And the ESS scores of combination group were higher than those of the ozagrel group （P〈0.05）. After 14 days of treatment, the effective rate was 76.8 % in the combination group and 60.9 % in the ozagrel group. The effective rate of combination group was higher （P〈0.05）. After therapy, the Barthel scores of two groups was higher than before therapy （P〈0.05）. And the Barthel scores of combination group were higher （P〈0.05）. During 1 month follow-up, there were no statistical significance in adverse reactions between two groups （P〉0.05）. Conclusion： The oragrel combined with piracetam could improve the neurological fimction and Barthel of patients with acute cerebral infarction with good safety, worthy of clinical use.

关 键 词：奥扎格雷 吡拉西坦 急性脑梗死 生活能力 不良反应 

分 类 号：R743[医药卫生—神经病学与精神病学]